Targeting GLUT1 to Control Autoimmunity in Type 1 Diabetes

10 out of 12 people cured in Type 1 Diabetes Study

Article URL: Comments URL: Points: 15 # Comments: 2

<![CDATA[GLP-1 Access Depends on Smarter Benefit Design and Patient Support]]>

Resetting autoimmune disease with CAR cell therapies

Explore the potential of CAR T cells in autoimmune diseases: a novel way to target B cells, reset immunity, and meet clinical gaps! PMID:421

Depletion of extracellular asparagine impairs self-reactive T cells and ameliorates autoimmunity in a murine model of multiple sclerosis

Amino acids play critical roles in the activation and function of lymphocytes. Here we show that the non-essential amino acid, asparagine, i

How many Canadian employers are offering GLP-1 coverage for weight loss?

Cost control, eligibility requirements, and health risks of obesity among key factors shaping employer approach to medication: IFEBP survey

NHS rolls out teplizumab immunotherapy to delay type 1 diabetes onset by three years

The immunotherpay can give children and adults three extra years before they need to use insulin.